SAR3419 meets in Phase II trial in DLBCL

IV SAR3419 from ImmunoGen Inc. (NASDAQ:IMGN) and partner Sanofi (Euronext:SAN; NYSE:SNY) led to an overall response rate (ORR) of 43.9% in the Phase II STARLYTE trial to treat diffuse large B cell lymphoma (DLBCL) -- meeting the primary endpoint in the trial of an ORR of 20% or greater. The data came from 41 patients with relapsed or relapsed/refractory CD19-positive DLBCL in the per protocol population. Patients in the trial are receiving once-weekly SAR3419 for four weeks and then every other week until disease progression or discontinuation. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...